- 4-Week Delivery: World’s fastest custom mouse model development.
- TurboMice™ Tech: Proprietary high-efficiency gene-editing platform.
- Full Capabilities: Expert conditional knockouts, knock-ins, and humanized models.
- Validated Quality: Guaranteed high precision and model viability.
Humanized SOD1 Mouse Model
| Strain Name | Humanized SOD1 Mouse Model (C020) |
|---|---|
| Editing Type | Humanized/Knockin |
| Gene Name | SOD1 (human superoxide dismutase 1); endogenous mouse *Sod1* replaced |
| Gene Synonyms | Human: ALS / SOD / ALS1 / IPOA / STAHP / hSod1 / HEL-S-44 / homodimer;Mouse: Ipo1 / SODC / Ipo-1 / Sod-1 / CuZnSOD / Cu/Zn-SOD / B430204E11Rik |
| Strain Background | C57BL/6N |
| NCBI No. | SOD1 (human) 6647;Sod1 (mouse) 20655 |

1. ALS mechanism at endogenous expression levels Examine how familial ALS-linked human SOD1 variants (G93A, G37R, G85R) alter protein folding, dimer stability, metal loading and aggregation when the human gene sits at the mouse Sod1 locus instead of being carried on a multi-copy transgene.
2. Human-specific therapeutic validation and preclinical safety Test antisense oligonucleotides, siRNAs, antibodies, degrader molecules and gene-editing reagents that discriminate human SOD1 from mouse Sod1, and run efficacy plus safety readouts in a host in which the mouse gene has been replaced.
3. Cu/Zn superoxide dismutase biology and protein quality control Use the wild-type humanized line to study dismutase function — superoxide clearance, hydrogen peroxide handling and redox balance — without the overexpression burden of a transgenic line, and to separate human-protein dosage effects from mutation-specific effects.
The humanized SOD1 mouse model replaces the coding sequence of the endogenous mouse Sod1 gene with human SOD1 by homologous recombination, so that expression remains under the control of the native Sod1 regulatory elements. SOD1 encodes the cytosolic Cu/Zn superoxide dismutase, a homodimeric enzyme that converts superoxide anion to hydrogen peroxide. It was the first gene linked to familial amyotrophic lateral sclerosis (1993); more than 180 disease-causing variants are now documented, accounting for roughly 20% of familial ALS and a higher share in Asian cohorts. SOD1-linked disease arises from a toxic gain of function rather than from loss of dismutase activity — variants that retain and variants that abolish enzymatic activity both cause disease, and Sod1 null mice do not develop ALS. The model therefore supports work on human SOD1 protein behaviour and on human-specific reagents in a background where mouse Sod1 has been replaced, with G93A, G37R, G85R or wild-type human SOD1 built on the same C57BL/6N background.
- Human SOD1 under native control. The human gene occupies the mouse Sod1 locus and is driven by the endogenous regulatory elements, so tissue and developmental expression follows the normal pattern rather than a randomly integrated construct; copy number is fixed by breeding, not by integration site.
- Named clinical variants on one background. G93A, G37R and G85R — three widely used experimental variants — can be produced with the same editing strategy on C57BL/6N, so mutation effects can be compared without confounding differences in construct, copy number or genetic background.
- A clean host for human-specific tools. Oligonucleotides, antibodies and degraders that recognize human but not mouse SOD1 need a background in which mouse Sod1 is absent; residual mouse protein otherwise competes for the same reagent and dilutes the readout.
- Physiological expression instead of 20–25 copies. The reference G93A line (Gurney 1994) carries roughly 20–25 copies of a human SOD1 transgene, develops motor deficits around 80–120 days of age and reaches end stage near 130 days; copy number rather than the mutation alone sets that timeline, and high-copy lines also show CNS vacuolation that is rare in patients. Expression from the native locus removes that copy-number artefact.
- Wild-type and mutant side by side. A wild-type human SOD1 line from the same design separates mutation-driven effects from human-protein dosage effects — relevant because wild-type human SOD1 expressed at G93A-line levels is itself capable of producing an ALS-like phenotype, and co-expression of wild-type with mutant protein worsens outcome.

FAQ
Game-changing benefits?
While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.
How much for a project assessment?
•Free initial design proposal with zero obligations.
•Request a free quote!
Who owns the mouse lP? Do l need a licence from Mingceler?
All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.
